



Review

p53 Activation in Genetic Disorders: Different Routes to the Same Destination

Yu-Young Tsai [†], Chun-Hao Su [†] and Woan-Yuh Tarn ^{*,†}

Institute of Biomedical Sciences, Academia Sinica, Taipei 11529, Taiwan;
wesleytsai1999@ibms.sinica.edu.tw (Y.-Y.T.); chsu@ibms.sinica.edu.tw (C.-H.S.)

* Correspondence: wtarn@ibms.sinica.edu.tw; Tel.: +886-2-2652-3052

[†] These authors contributed equally to this work.

Abstract: The tumor suppressor p53 is critical for preventing neoplastic transformation and tumor progression. Inappropriate activation of p53, however, has been observed in a number of human inherited disorders that most often affect development of the brain, craniofacial region, limb skeleton, and hematopoietic system. Genes related to these developmental disorders are essentially involved in transcriptional regulation/chromatin remodeling, rRNA metabolism, DNA damage-repair pathways, telomere maintenance, and centrosome biogenesis. Perturbation of these activities or cellular processes may result in p53 accumulation in cell cultures, animal models, and perhaps humans as well. Mouse models of several p53 activation-associated disorders essentially recapitulate human traits, and inactivation of p53 in these models can alleviate disorder-related phenotypes. In the present review, we focus on how dysfunction of the aforementioned biological processes causes developmental defects via excessive p53 activation. Notably, several disease-related genes exert a pleiotropic effect on those cellular processes, which may modulate the magnitude of p53 activation and establish or disrupt regulatory loops. Finally, we discuss potential therapeutic strategies for genetic disorders associated with p53 misactivation.

Keywords: centrosome; developmental disorders; DNA damage repair; p53; ribosome; telomere



Citation: Tsai, Y.-Y.; Su, C.-H.; Tarn, W.-Y. p53 Activation in Genetic Disorders: Different Routes to the Same Destination. *Int. J. Mol. Sci.* **2021**, *22*, 9307. <https://doi.org/10.3390/ijms22179307>

Academic Editors: Andreas Prokesch and Jelena Krstic

Received: 9 August 2021

Accepted: 25 August 2021

Published: 27 August 2021

Publisher's Note: MDPI stays neutral with regard to jurisdictional claims in published maps and institutional affiliations.



Copyright: © 2021 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (<https://creativecommons.org/licenses/by/4.0/>).

1. Introduction

The p53 gene is most frequently altered in human malignancies, indicating its biological and clinical importance [1]. p53 transactivates approximately one hundred target genes that exert diverse biological functions—primarily cell cycle regulation, DNA repair, and apoptosis [2,3]. p53 also represses gene expression via the action of its downstream targets, such as p21 [3]. Given the role of p53 in tumor suppression, *Trp53* ablation induces tumors in mice at an early age [4]. Moreover, *Trp53* knockout mice exhibit developmental abnormalities, which, however, differ between strains of mice with different genetic backgrounds, indicating that p53 contributes to cell differentiation and development [5]. p53 also participates in various metabolic pathways and coordinates metabolic homeostasis; dysregulation of p53 function may lead to metabolic disorders and perhaps tumorigenesis [6]. Moreover, p53 regulates cell senescence and aging through multiple signaling pathways [7]. In response to cellular stress(es) of different types or intensities, p53 may induce transient cell-cycle arrest to allow damage repair or evoke senescence or apoptosis that, respectively, halts damage propagation and eliminates damaged cells [8]. Abnormal and/or persistent p53 activation promotes tissue degeneration [9]. For example, excess p53-induced neuronal death is linked to neurodegenerative diseases such as Alzheimer's disease [9]. Additionally, excessive p53 activation during embryonic development has been observed in a variety of congenital disorders [10]. In this review, we discuss several sets of genetic mutations that contribute to excessive p53 activation, leading to phenotypic abnormalities in congenital disorders.

2. Molecular Function and Regulation of p53

p53 is a master regulator of cell-fate determination in response to cellular stress or DNA damage, primarily via its role in transcriptional regulation. Upon genotoxic or oncogenic insults, p53 activates the expression of genes involved in DNA damage repair, cell-cycle arrest, apoptosis, senescence, and autophagy [11,12]. p53 directly participates in various DNA repair pathways to maintain genome stability [13]. In addition, cytoplasmic p53 can inhibit autophagy and promote apoptosis or necrosis [14,15]. Deregulation of p53 function may lead to metabolic dysfunction, aging, or tumorigenesis [6]. In human cancer, mutant p53 in general loses its ability to suppress tumorigenesis and may, however, gain oncogenic potential such as promoting tumor cell survival or adaptation to stress [16,17].

The expression of p53 is regulated by multiple signaling pathways and mechanisms. In non-stressed cells, p53 level is restricted primarily by Mdm2-mediated ubiquitination and proteasomal degradation, thereby constraining its anti-proliferation and pro-apoptotic functions [18] (Figure 1A). However, DNA damage or oxidative stress results in phosphorylation of Mdm2 and p53, leading to disruption of the Mdm2-p53 interaction. The level of p53 protein is consequently increased (Figure 1B). In addition to the ubiquitination activity toward p53, Mdm2 can suppress the transactivation activity of p53 [19]. DNA damage induces acetylation of p53 and releases p53 from repression by Mdm2 or its homolog Mdm4, leading to activation of p53-responsive target genes [18] (Figure 1C). Moreover, additional phosphorylation/dephosphorylation events and various types of post-transcriptional modifications such as acetylation and SUMOylation can also modulate p53 stability or activity [18,19] (Figure 1D).




Figure 1. Regulation of p53 gene expression and protein stability/activity. (A) In unstressed cells, p53 is subjected to Mdm2-mediated ubiquitination, followed by proteasome-dependent degradation. (B) Under stressed conditions, phosphorylation of Mdm2 and p53 prevents their interaction, thereby stabilizing p53. (C) Cellular stressors, such as DNA damage, may relieve p53 from Mdm2/Mdm4-mediated suppression from promoters. For full transcriptional activation of p53-responsive genes, p53 may undergo various post-translational modifications and recruit promoter-specific cofactors. (D) Depicted are additional molecular mechanisms by which p53 gene/protein expression is regulated. Abbreviations: UTR, untranslated region; ORF, open reading frame.

Besides post-translational modification, cellular p53 level can be regulated via mRNA stability or translational control [20]. A large set of miRNAs act as negative regulators of p53 by promoting mRNA degradation [21]. In response to DNA damage, p53 mRNA translation is activated by ribosomal protein L26 (Rpl26) or derepressed from programmed cell death protein 4 (Pdc4)-mediated suppression [22,23] (Figure 1D). Moreover, p53 isoforms that are generated by alternative transcriptional initiation, alternative splicing, or alternative translation initiation have been detected in various types of cancer or can be induced in response to cellular stimuli [24] (Figure 1D). Those N- or C-terminally truncated p53 isoforms may positively or negatively modulate the transcriptional activity of p53 or act independently. Certain p53 isoforms, such as $\Delta 40p53$, are relatively more stable [25]. Co-expression of wild-type or mutant p53 isoforms in cancer cells, however, results in diverse effects on tumorigenesis [26]. Finally, some of the p53 isoforms contribute to embryonic development, neurodegeneration and inflammation, indicating their physiological and pathological significance [27–29].

3. p53 Activation Associated with Congenital Anomalies

Studies of gene mutants or knockouts in mouse models have revealed that inappropriate p53 activation accounts for different extents of developmental defects [30]. Phenotype severity correlates with the degree of p53 activation. For example, homozygous knockout of *Mdm2* results in early embryonic lethality [31]. As compared to *Mdm2*-null mice, *Mdm2*^{Puro} heterozygotes express modest levels of Mdm2 and hence exhibit mild p53 activation. These mice were alive, albeit with a short lifespan and hematopoietic defects [32]. Some p53 mutants display a higher stability or activity. Mice of strains with such mutant p53 die at different embryonic stages with tissue-specific defects, or have reduced lifespan and premature aging phenotypes [10]. For example, the p53^{7KR} mutant bearing mutations in the C-terminal acetylation/ubiquitination sites has higher basal expression and transactivation activity towards the cell-cycle inhibitor p21 than does wild-type p53 [33]. The p53^{25,26,53,54} mutant by itself is transcriptionally inactive due to mutations in the transactivation domains, but it can stabilize and hence upregulate wild-type p53 [34]. The increase in p53 protein, either by stabilizing p53 or by inactivating Mdm2/4, causes diverse phenotypes—from embryonic lethality to developmental defects such as craniofacial malformation, microcephaly, and reduced bone marrow cellularity [10]. It is possible that excessive p53 activity inhibits proliferation and/or induces apoptosis of stem/progenitor cells, resulting in hypoplasia. A recent study using mouse models demonstrates that the cellular level as well as the spatiotemporal expression pattern of p53 determines the nature and severity of developmental syndromes [10].

Similar to the above mouse models, a variety of human congenital disorders arises from inappropriate activation of wild-type p53. First described in 1900, the Treacher Collins syndrome (TCS) is a rare genetic disorder that exhibits multiple facial dysmorphisms [35]. *TCOF1* is the primary gene associated with TCS, encoding an RNA polymerase I associated factor that regulates ribosome biogenesis [35]. *Tcof1* deficiency results in decreased proliferation of both neural ectoderm and neural crest cells, and this underlies the observed craniofacial anomalies in TCS [36]. Nucleolar stress triggers stabilization and activation of p53, whereas inhibition of p53 activity prevents craniofacial maldevelopment, providing a pathological link between ribosomal defects and aberrant p53 activation [37,38]. Excessive p53 activation is a notable contributor to human disorders of ribosome dysfunction, namely ribosomopathies such as Diamond Blackfan anemia (DBA) and 5q⁻ syndrome [39,40]. Analogous to ribosomopathies, several congenital disorders also exhibit p53 upregulation, including Fanconi anemia (FA, with genetic defects in DNA damage repair and response), dyskeratosis congenita (DC, telomere replication defects), and primary microcephaly (centrosome duplication defects) [41–43]. Because disruption of any of these cellular activities may result in chromosome and/or genome instability, p53 activation is a conceivable consequence. Generally, loss of p53 can rescue—at least to some extent—the phenotypes of mouse models of p53 activation-associated human congenital disorders, indicating that

excessive p53 leads to congenital abnormalities [10]. In addition to the aforementioned disorders, mutation of several tissue-specific transcription or chromatin remodeling factors, namely Chd7, Tbx1, and Pax3, is also linked to p53 activation-associated disorders such as CHARGE, 22q11.2 deletion, and Waardenburg syndromes, respectively. We refer interested readers to recent reviews [44–46].

4. Genetic Disorders Related to Excessive p53 Activation

4.1. Disorders of Ribosome Dysfunction

Ribosome biogenesis is a major determinant of translational capacity. Neoplastic transformation requires upregulation of both ribosome biogenesis and translation, whereas certain congenital diseases result from defects in ribosome assembly. DBA syndrome, which is characterized by chronic macrocytic–normocytic anemia, is a typical example of ribosomopathies [39,47]. Approximately 20 DBA-associated genes encode ribosomal proteins (RPs) or factors that participate in rRNA processing or ribosomal biogenesis [39,40] (Figure 2A). For example, mutations in *RPS19* have been identified in ~25% of affected individuals. *Rps19* knockout mice develop macrocytic anemia, as observed in DBA patients [48]. *Rps19* deficiency impairs cell proliferation and induces apoptosis of hematopoietic progenitors. Genetic ablation of p53 can help restore the normal phenotype, and the effect depends on the extent of ablation. Analogously, haploinsufficiency of *Rps14*, a causal factor in 5q⁻ syndrome, also leads to macrocytic anemia [49]. Knockout of p53 rescues the defect in bone marrow progenitor cells. As described above, mutations in rDNA transcription factors such as *TCOF1* that are linked to TCS also cause p53 activation [38]. Therefore, excess p53 activation, secondary to ribosome deficiency, accounts for the depletion of hematopoietic stem/progenitor cells (HSPCs). Inactivation of p53 alleviates the pathobiology of ribosomopathies.

Disruption of ribosome biogenesis as a consequence of RP mutations or impaired rRNA synthesis results in free RPs that are not incorporated into ribosomes. Unincorporated RPs can bind to and inhibit Mdm2, thereby increasing the half-life of p53 (Figure 2A). Increased p53 activity can trigger cell apoptosis [50]. The extra-ribosomal functions of certain RPs may also contribute to pathogenesis of ribosomopathies [51,52]. For example, Rpl11 destabilizes *c-Myc* mRNA by recruiting the RNA-induced silencing complex, leading to suppression of *c-Myc* target genes [53,54]. Therefore, *c-Myc* activity is likely upregulated in *Rpl11*-deficient cells. Accordingly, *Rpl11* haploinsufficient adult mice have increased susceptibility to lymphomagenesis under genotoxic stress in part by upregulating *c-Myc* [55]. A notable feature of ribosomopathies is the tissue-specificity of clinical presentation. One explanation is that reduced ribosome levels may selectively compromise the translation of certain cell-type specific mRNAs [51,52]. For example, the translation of GATA1, a master transcription factor for hematopoietic genes, is particularly impaired in RP-deficient DBA cells, perhaps owing to secondary structures in its 5' untranslated region [56]. A follow-up study revealed that reduced ribosome abundance in hematopoietic cells with DBA-associated lesions indeed impairs the translation of a set of master regulators for erythroid differentiation [57]. Another possible explanation for tissue specific phenotypes of ribosomopathies is ribosome heterogeneity, in which RP composition or rRNA modification is altered [58,59]. Ribosome heterogeneity may contribute to specialized translation, resulting in lineage-biased protein expression. In general, ribosomal defects alter the cellular translational landscape and rewire metabolic programs, shifting cells towards an oncogenic state. Therefore, ribosome heterogeneity/specialization provides an explanation of how congenital ribosomopathies display hypoproliferative anemia during infancy and early childhood and have an increased cancer risk later in life [51,52].




Figure 2. Cellular processes implicated in p53 hyperactivation-associated genetic disorders. Genetic alterations (mutation/deletion; red circle in the center) lead to their respective human congenital disorders (orange zone) via disruption of various cellular processes or activities, including ribosome biogenesis (A), DNA damage repair (B), telomere maintenance (C), and centrosome duplication (D) as depicted in the four quadrants. p53 hyperactivation as a common feature shared across these genetic aberrations in murine models is depicted in the most center of this figure. The resulting molecular and cellular defects (yellow zone) underlie each group of disorders. Red ovals indicate the encoded proteins that, when dysregulated or absent, contribute to the syndrome discussed in the text. Hyperactive p53 is represented by a bold red-filled circle, as opposed to p53 at baseline in white-filled circle. Abbreviations: RCP, Richieri-Costa-Pereira; RS, Revesz syndrome; LIS4, Lissencephaly-4.

The two genes, *EIF4A3* and *RBM8A*, encoding nonsense-mediated mRNA decay factors, have been implicated in Richieri-Costa-Pereira syndrome and thrombocytopenia absent radius (TAR) syndrome, respectively [60–62]. Heterozygous knockout of either gene in the mouse neocortex causes microcephaly, accompanied by p53 activation; knockout of p53 allows for a partial rescue of cortical development [63,64]. TAR syndrome is characterized by the absence of the radius bone and thrombocytopenia. Accordingly, *Rbm8a* ablation in megakaryocyte precursors severely reduces the platelet count in mice [65]. It is possible that elevated p53 impairs polyploidization of megakaryocytes. p53 knockout partially restored the level of platelets in *Rbm8a* knockout, supporting that TAR is also a p53 activation-related disorder. Notably, transcriptome analysis reveals a reduction in the

expression of ribosomal protein mRNAs, indicating that *Rbm8a* deficiency may compromise ribosome biogenesis [64]. *Rbm8a* deficiency also results in centrosome aberrations and DNA damage accumulation [66–68], which have the potential to induce p53. In addition, *RBM8A* (Y14) depletion inhibits ubiquitination of p53 and thus stabilizes p53 in cell cultures [69]. Therefore, *RBM8A* deficiency may induce p53 activation via multiple pathways. Finally, given that TAR syndrome results from a deletion of a ~200 kb 1q21.1 region that encompasses *RBM8A* as well as another 15 genes, whether and how haploinsufficiency of these genes contributes to TAR pathogenesis remains obscure.

4.2. Disorders Related to DNA Repair Deficiency

DNA repair defects cause a broad spectrum of clinical phenotypes, including neurological disease, accelerated aging, and cancer predisposition. In addition, deficiency in certain DNA repair pathways, i.e., the FA pathway, double-strand DNA break (DSB) repair and DNA damage response (DDR), is particularly associated with inherited developmental disorders [70].

The FA pathway is involved in the repair of DNA interstrand crosslink (ICLs), which generally cause replication arrest and may also give rise to DSBs [71] (Figure 2B). The FA complex consisting of ~20 FA factors detects stalled replication forks and triggers the ATR-Chk1 cell-cycle checkpoint along with a series of reactions involving post-translational modifications of FA factors to resolve ICLs [72,73]. The FA pathway ensures repair fidelity for ICL-derived DSBs by promoting homologous recombination (HR) over the competing non-homologous end joining (NHEJ) repair pathway. Notably, *BRCA1/2* (Fancs/Fancd1) play a critical role in HR. The FA/BRCA pathway also resolves DNA replication stresses induced by transcription–replication collision, DNA–RNA hybrids, or G-quadruplexes [74]. Dysfunction of FA-associated pathways leads to the accumulation of DNA damage with consequent increased chromosomal instability.

The majority of FA patients develop bone marrow failure; among them, more than half suffer from congenital defects such as microcephaly and skeletal abnormalities [75]. Bone marrow failure results from progressive impairment of HSPCs [76]. Constitutive p53 induction is observed in FA fibroblasts [77]. *Fancd2* knockout in mice induces G0/G1 cell-cycle arrest in HSPCs, which can be rescued by knockdown of p53 or p21, indicating that an elevated p53/p21 response impairs hematopoiesis [77]. It is likely that, during fetal development of FA-afflicted subjects, excess p53 activation that results from replicative stress diminishes the pool of HSPCs, leading to bone marrow failure. Notably, *Fanca* or *Fancc* knockout reduces the capacity for NPC self-renewal during developmental and adult neurogenesis [78]. Conceivably, excessive p53 accounts for aging-associated neural stem cell exhaustion in such FA mouse models. Mutations in the genes that are involved in both the FA and HR pathways such as *BRCA1*, *RAD51* and *XRCC2* confer susceptibility to cancer [70]. Biallelic mutations in any of these genes cause embryonic lethality that can be partially rescued by p53 knockout [79–81], indicating that reduction of p53 may restore cell cycle and/or prevent cell death.

DSB repair involves HR or NHEJ. Besides the aforementioned HR/FA factors, defective NHEJ genes are also linked to congenital disorders (Figure 2B). Mutations in *LIG4*, *XLF* or *PRKDC* cause profound immunodeficiency and/or microcephaly [82]. NHEJ plays a critical role in lymphocyte development by resolving the programmed DSBs generated during V(D)J recombination. Therefore, NHEJ defects compromise the immune system. As observed in FA genes, knockout of any of the NHEJ genes (*Lig4*, *Xrcc4* or *Prkdc*) causes excessive neuronal apoptosis and this defect can be rescued by co-deletion of the p53 gene [83–85]. The Mre11–Rad50–Nbs (MRN) complex has multiple functions in DDR, including DSB recognition, DNA replication fork stabilization, and telomere maintenance [86] (Figure 2B). Mutations in *NBS1/NBN* and *RAD50*, respectively, cause Nijmegen breakage syndrome (NBS) and an NBS-like disorder, with consequent microcephaly, but only the former suffers from immunodeficiency [87]. Knockout of *Nbn* in the central nervous sys-

tem results in microcephaly as well as cerebellar ataxia, which can be rescued by p53 ablation [88].

In conclusion, DNA repair impairment causes genome instability and activates p53-mediated cell-cycle arrest or apoptosis that constrains the size of the hematopoietic/neural stem cell pools, leading to bone marrow failure or microcephaly. Finally, it is noteworthy that an increased p53 activity attenuates the FA DNA repair pathway and hence exacerbates DNA damage, suggesting a positive feedback loop [89].

4.3. Syndromes Caused by Telomere Dysfunction

Telomeres protect the ends of eukaryotic chromosomes to prevent chromosomes from fusion and degradation, thus maintaining chromosome length and therefore genome integrity [90]. Telomere shortening is associated with aging. On the other hand, upregulation of the telomere maintenance mechanism is a common feature of cancer [91]. Telomeres consists of thousands of hexameric TTAGGG repeats, and telomere replication is catalyzed by the telomerase, a ribonucleoprotein complex containing the RNA template *Terc*, the reverse transcriptase *Tert*, and several additional factors including the pseudouridine synthase Dyskerin (*Dkc1*). *Dkc1* binds to the H/ACA box of the telomerase RNA, which is a hairpin structure also characteristic of a class of small RNAs in the nucleolus or Cajal bodies [92]. In addition, the shelterin complex, which consists of six different subunits, binds to both double-stranded and single-stranded telomeric repeats and also plays a critical role in maintaining chromosome stability by preventing hyper-resection at telomeres (Figure 2C).

Telomere disorders (also called telomeropathy syndromes) are characterized by genetic deficits in telomere maintenance, including the archetypal DC syndrome and its variants such as Hoyeraal Hreidarsson syndrome and Revesz syndrome. DC exhibits high rates of bone marrow failure as well as other symptoms such as cutaneous pigmentation and nail hypertrophy [41]. DC is caused by germline mutations of genes that participate in telomere biogenesis, including telomerase (*DKC1*, *TERC*, *TERT*), the shelterin complex (*TIN2*, *TPP1*), and telomere elongation helicase *RTEL1* [41] (Figure 2C). The most prevalent mutations in DC occur in *DKC1*, *TERC*, *TERT*, and *TIN2*. *Dkc1* regulates the accumulation of the human telomerase RNA. DC-associated mutations of *DKC1* not only cause destabilization of telomerase RNA and telomere shortening but also impair ribosome biogenesis [92]. *Dkc1* knockout results in activation of the p53-dependent cell-cycle checkpoint pathway [93]. DC-associated mutations in three other telomerase or shelterin genes, namely *TERC*, *TERT*, and *TIN2*, also impair telomere integrity and induce p53 expression [94]. *Terc* knockout-induced telomere shortening impairs adult neurogenesis in the lateral ventricles of the brain; p53 ablation rescues such defects [95]. Knockout of the telomere shelterin component *Acd/Top1* in epidermal keratinocytes results in skin hyperpigmentation and impairs hair-follicle morphogenesis, both of which are also reversed by p53 knockout [96].

It is intriguing that reduced telomerase activity or telomere shortening has been observed in defects of a number of non-telomerase factors. For example, the poly(A)-specific ribonuclease PARN is involved in mRNA turnover by degrading the poly(A) tail of mRNAs. Hoyeraal Hreidarsson syndrome-associated mutations in *PARN* result in telomere shortening [97]. *PARN* deficiency downregulates telomerase RNA and several transcripts encoding telomere-related factors, hence compromising telomerase activity [97]. A missense mutation of *MDM4* (T454M) has been identified in individuals with DC-like phenotypic traits [98]. However, homozygous *Mdm4*^{T454M} mutation causes neonatal death, but embryonic fibroblast cells derived from *Mdm4*^{TM/TM} mice exhibit increased p53 level and decreased telomere length, a cardinal feature of telomeropathies [98]. Homozygous p53 mutant (p53^{Δ31/Δ31}) mice express a C-terminally truncated and hyperactive form of p53 phenocopy telomere disorder syndromes. Telomeres in such p53^{Δ31} mutant cells are significantly shorter than those in wild-type cells [99]. It appears that p53 activation downregulates the expression of several genes involved in telomere metabolism, including *Dkc1*, *Rtel1*, and *Tin2* [99,100], but how this regulation achieves gene specificity remains unclear.

Collectively, severe telomere shortening activates p53, which may further compromise telomerase activity, suggesting a regulatory loop which exacerbates telomere shortening.

4.4. Disorders Related to Centrosome Dysfunction

The centrosome is an evolutionarily conserved cylindrical organelle that acts as the main microtubule-organizing center to direct bipolar mitotic spindle assembly for accurate segregation of chromosomes during cell division. The centrosome contains two centrioles in orthogonal configuration surrounded by pericentriolar material that harbors proteins responsible for microtubule nucleation and anchoring and regulating cell-cycle checkpoints [101] (Figure 2D). Centriole duplication is coupled with the cell cycle in a highly spatiotemporally regulated manner [101]. Upon exit from mitosis, centriole pairs disengage and duplicate at the G1/S transition, and subsequently centrosomes become mature and separated. By metaphase, centrosomes move to opposing poles of the cell to dictate the organization of the mitotic spindles for chromosome separation. Deregulation of centrosome biogenesis leads to structural or numerical aberrations of centrosomes [102]. Centrosome abnormalities are observed in most cancer types, which may result from deregulation of oncogenes or tumor suppressors or perturbation of cell cycle progression. Centrosome aberrations may consequently cause chromosomal instability and perturb asymmetric cell division. Notably, centrosome aberrations can trigger an immunosuppressive microenvironment and promote dissemination of metastatic cells [103,104], emphasizing the impact of centrosome abnormalities in tumorigenesis.

A large set of centrosomal factors participate in centriole duplication and stability control, γ -tubulin recruitment and centrosomal attachment of the γ -tubulin ring complex [105]. Mutations in these centrosome-related genes cause developmental defects—primarily microcephaly and also growth failure [106]. Among disorders induced by centrosome aberrations, microcephaly primary hereditary (MCPH) is the most extensively studied. Notably, nine of the 27 MCPH-associated genes are implicated in centriole biogenesis and/or the coupling of the centrosome cycle and mitosis [107] (Figure 2D). *ASPM* (*MCPH5*) mutations represent the most common cause of MCPH. *Aspm*, which localizes to centrosomes and spindle poles, is required for spindle organization and positioning [108]. *Aspm* knockout in cerebellar granule neuron progenitors alters cell-division orientation and induces premature differentiation and apoptosis. Knockout of *Bax* or p53 restores cerebellar growth of *Aspm*-deficient mice [109]. *Aspm* functions coordinately with the citron Rho-interacting kinase *CitK* to regulate mitotic spindle orientation [110]. Notably, loss or inactivation of *CitK* also causes primary microcephaly and p53 ablation mitigates such phenotypes [111], suggesting that *CitK* deficiency causes p53-dependent microcephaly. In addition, mutations of several other centrosome-related genes, such as *PCNT*, *CENPJ*, *CEP152*, and *CEP63*, are linked not only to MCPH but also to Seckel syndrome, characterized by dwarfism in addition to microcephaly [112]. *Cep63* localizes to the centrosome but dissociates upon DNA damage. *Cep63* and *Cep152* act in concert to ensure efficient centriole duplication [113]. *Cep63* deficiency compromises centriole duplication, leading to mitotic spindle defects in NPCs. Hence, delayed mitosis triggers p53-induced apoptosis, as observed in *Aspm* knockout mice; knockout of p53 restores the number of NPCs [114].

Nde1 is a candidate gene for lissencephaly-4, which is characterized by both microcephaly and lissencephaly. *Nde1* is a centrosomal factor that regulates mitotic spindle assembly and also is necessary for dynein function [115] (Figure 2D), which contributes to interkinetic nuclear migration and mitosis of radial glial cells. Therefore, *Nde1*-null mice exhibit severe microcephaly. *Nde1* mutant NPCs undergo p53-dependent apoptosis owing to catastrophic DNA damage, leading to neuron depletion in the middle cortical layers [105]. p53 depletion is sufficient to restore cortical development and brain size in knockout mice.

In summary, mutations in centrosome-related genes can result in defective centriole duplication or spindle orientation in NPCs, leading to apoptosis of progeny cells. A recent report indicated that centrosome defects in NPCs cause delayed mitosis, which triggers

a mitotic surveillance pathway [116]. Consequently, p53-dependent apoptosis of NPCs reduces cortical expansion and hence causes microcephaly.

In conclusion, dysregulation of the aforementioned yet different cellular processes during development commonly lead to stabilization or induction of p53. A high level of p53 in general induces cell cycle arrest and/or apoptosis of various stem and progenitor cells, and hence result in phenotypic abnormalities, such as microcephaly, bone marrow failure, and craniofacial deformation, in respective genetic disorders (Figure 3).




Figure 3. Genetic impact activates the p53 networks resulting in developmental abnormalities. Genetic alterations that disrupt several different cellular processes as depicted lead to upregulation of p53 networks, which leads to stem cell deficiency-associated phenotypic abnormalities. Gene mutations also have direct impact on phenotypes.

5. Interrelationships of the Cellular Processes Implicated in p53 Activation-Associated Disorders

Several aforementioned disease genes may exert pleiotropic effects on different cellular processes (Figure 4). For example, *Dkc1* mutations not only cause telomere shortening, but also impair ribosome biogenesis and subsequently compromise mRNA translation [117,118]. Notably, *PARN* deficiency particularly downregulates the transcripts encoding factors involved in telomere maintenance, including *Dkc1* [97]. Therefore, impaired rRNA biogenesis is observed in *PARN*-mutated or knockout cells. Perhaps compromised translation resulting from defective rRNA modification/processing can explain the tissue-specific symptoms and cancer predisposition found in DC patients [119]. The recently identified MCPH gene *RRP7A* encodes an 18S rRNA processing factor. Intriguingly, Rrp7a also localizes to the centrosome and cilia. MCPH-derived dermal fibroblasts display defects in rRNA processing and ciliary dynamics. *Rrp7a* knockout zebrafish exhibit microcephaly-like phenotypes [120]. Thus, it would be interesting to know whether and how Rrp7a links centrosome dynamics and rRNA biogenesis during cortical development, and whether p53 inactivation is sufficient to revert phenotypes caused by *Rrp7a* deficiency.

Centrosome biogenesis is tightly controlled throughout the cell cycle and is sensitive to DNA damage. After DNA damage, DDR kinases ATM/ATR delocalize Cep63 from the centrosome to prevent centrosome-dependent microtubule assembly [121]. Abnormal centrosome numbers are frequently observed in fibroblasts of FA patients. Indeed, several FA proteins localize to the mitotic apparatus during cell division and help ensure the fidelity of chromosome segregation [122]. Inactivation of the FA pathway leads to spindle checkpoint failure and induces supernumerary centrosomes. Recent reports have indicated that Fanca and Fanci play a role in ribosome biogenesis or nucleolar homeostasis, suggesting a potential link between DNA damage and nucleolar stress responses [123]. In addition to mRNA surveillance, *RBM8A* participates in DNA damage repair and centrosome organization [66–68]. It is conceivable that several critical cellular processes that span genome integrity, mRNA/protein expression, and cell cycle/division, are interrelated to ensure proper cellular function.




Figure 4. Dysregulation of biological processes that activate p53 and their interconnection. Colored ovals depict protein factors encoded by congenital disorder-associated genes. These factors participate in multiple biological processes. Dysregulation of each biological process (blue grey) activates p53.

Finally, it is plausible that multiple defective processes that result from a single mutant gene converge on p53 signaling; consequently, differential degree of p53 activation may influence the tissue specificity of cellular defects.

6. Therapeutic Strategies for p53 Activation-Associated Disorders

As demonstrated by using animal models, p53 activation-induced developmental defects can be rescued, albeit often partially, by concomitant deletion of p53. This possibility makes pharmacological attenuation of hyperactive p53 an attractive therapeutic strategy. Pifithrin- α is thought to inhibit p53-dependent transactivation; however, it prevents DNA damage-induced apoptosis, mitochondrial damage, and caspase activation, likely via multiple mechanisms [124]. Pifithrin- α restores erythroid differentiation of Rps14/19-

depleted CD34⁺ hematopoietic stem cells in vitro, indicating its potential in reversing the erythropoietic defects in DBA or 5q⁻ syndrome [125]. A recent report revealed that the FDA-approved calmodulin inhibitor trifluoperazine improves erythropoiesis in animal models of DBA by suppressing p53 mRNA translation [126]. Therefore, suppressing the expression or activity of p53 confers therapeutic value for p53 hyperactivation-associated disorders. siRNA-based p53 silencing may also be one of the future therapeutic approaches [127].

Besides direct inhibition of p53, a number of therapeutic strategies have been developed to target each cellular process discussed above. L-leucine upregulates mTOR signaling, subsequently promoting ribosome biogenesis and global translation via different molecular mechanisms. Administration of L-leucine improves anemia and increases bone marrow cellularity, accompanied by downregulation of p53 activity, in animal models of DBA [128,129]. Treatment with an antioxidant ameliorates craniofacial abnormalities by reducing the levels of DNA damage-induced reactive oxygen species in *Tcof1*-deficient animal models of TCS [130]. In addition, *Tcof* deficiency reduces the abundance of Cnbp/Znf9, which is an RNA binding protein required for the expansion of neural crest cells [131]. In a zebrafish model of TCS, inhibition of proteasomes can attenuate craniofacial malformations by restoring the level of Cnbp/Znf9 [132]. Treatment with danazol, an androgen derivative that aromatizes into estrogens, can upregulate *TERT* via nuclear receptors and hence promotes telomere elongation in DC patients [133]. Hyperactivated TGF- β signaling contributes to the suppression of hematopoiesis in bone-marrow failure disorders such as FA and myelodysplastic syndrome [134,135]. Therefore, pharmacological agents that inhibit TGF- β signaling constitute a potential therapeutic option for FA. Moreover, transducing gene-corrected autologous hematopoietic stem cells in patients is also a potential therapeutic strategy [136].

7. Conclusions and Outlook

Understanding the genetic causes and molecular mechanisms underlying the aforementioned congenital disorders may inform the development of therapeutic strategies. Over the past two decades, studies using tissue/cell-specific knockout mice have revealed that disruption of certain cellular processes can upregulate p53 and recapitulate developmental defects observed in the corresponding human disorders. In general, excess p53 restrains cell proliferation and/or induces apoptosis of various stem/progenitor cells during embryonic and/or postnatal development. However, many challenges remain in the quest to improve our understanding of p53 activation-associated disorders.

First, p53 suppression often partially rescues the mutant phenotypes of animal models of the aforementioned disorders, indicating that individual disorder-related factors may have specialized roles in cellular functions and development. Moreover, it must be noted that murine p53 isoforms are similar but not identical to their human counterparts. For example, depletion of TAR syndrome-associated *RBM8A* induces the isoform p53 β in human cells, which is absent in mice [69]. Therefore, the phenotypes of various disorders may be differentially affected by expression of the different p53 isoforms that are produced by humans or mice.

Second, it is important to know how mutations in different components of a macromolecular machine—such as the ribosome or centrosome—result in specific phenotypes besides the common ones. Therefore, future investigation should aim to reveal how different cell types confer differential tolerance to dysregulation of a certain cellular process. For example, to understand how ribosome heterogeneity contributes to the regulation of the proteome in various cell types, knock-in tagging experiments with a wild-type or mutant RPs (followed by Ribo-seq analysis) may help to reveal cell type-specific translatoemes [137].

Finally, regarding chromosome deletion syndromes such as 5q⁻ syndrome (5q33.1 deletion) and TAR syndrome (1q21.1 deletion), it is important to decipher how co-deleted genes contribute to pathogenesis. For example, different mouse models of 5q⁻ syndrome have been generated via deletion of a large chromosome interval syntenic to human 5q33.1, including *Rps14*, or co-deletion of *Rps14* with three other 5q⁻ syndrome genes

(*Csnk1a1/miRNA145/miRNA146a*) [49,138]. These mice recapitulate the features of 5q⁻ syndrome to different extents. Therefore, chromosome engineering, combinatorial gene deletions, and knock-in strategies will greatly facilitate the generation of mouse models that closely mimic human genetic disorders.

Funding: This research received no external funding.

Data Availability Statement: Not applicable.

Acknowledgments: This work was supported by the Ministry of Science and Technology grant 109-2811-B-001-529 to W.-Y.T.

Conflicts of Interest: The authors declare no conflict of interest.

Abbreviations

5q⁻: 5q⁻ syndrome; DBA: Diamond Blackfan anemia; DC: dyskeratosis congenita; DDR: DNA damage response; DSB: double-strand DNA break; FA: Fanconi anemia; HH: Hoyeraal Hreidarsson syndrome; HR: homologous recombination; HSPC: hematopoietic stem/progenitor cells; ICL: inter-strand crosslink; LIS4: lissencephaly-4; NBS: Nijmegen breakage syndrome; NHEJ: non-homologous end joining; NPC: neural progenitor cells; MCPH: microcephaly primary hereditary; MPD: microcephalic primordial dwarfism; PCM: pericentriolar material; RCP: Richieri-Costa-Pereira syndrome; RNPs: ribonucleoprotein particles; RPs: ribosomal proteins; RS: Revesz syndrome; SCID: severe combined immunodeficiency; TAR: thrombocytopenia absent radius; TCS: Treacher Collins syndrome.

References

- Levine, A.J.; Oren, M. The first 30 years of p53: Growing ever more complex. *Nat. Rev. Cancer* **2009**, *9*, 749–758. [CrossRef]
- Andrysiak, Z.; Galbraith, M.D.; Guarnieri, A.L.; Zaccara, S.; Sullivan, K.D.; Pandey, A.; MacBeth, M.; Inga, A.; Espinosa, J.M. Identification of a core TP53 transcriptional program with highly distributed tumor suppressive activity. *Genome Res.* **2017**, *27*, 1645–1657. [CrossRef]
- Fischer, M. Census and evaluation of p53 target genes. *Oncogene* **2017**, *36*, 3943–3956. [CrossRef]
- Jacks, T.; Remington, L.; Williams, B.O.; Schmitt, E.M.; Halachmi, S.; Bronson, R.T.; Weinberg, R.A. Tumor spectrum analysis in p53-mutant mice. *Curr. Biol.* **1994**, *4*, 1–7. [CrossRef]
- Jain, A.K.; Barton, M.C. p53: Emerging roles in stem cells, development and beyond. *Development* **2018**, *145*, dev158360. [CrossRef]
- Berkers, C.R.; Maddocks, O.D.; Cheung, E.C.; Mor, I.; Vousden, K.H. Metabolic regulation by p53 family members. *Cell Metab.* **2013**, *18*, 617–633. [CrossRef] [PubMed]
- Rufini, A.; Tucci, P.; Celardo, I.; Melino, G. Senescence and aging: The critical roles of p53. *Oncogene* **2013**, *32*, 5129–5143. [CrossRef] [PubMed]
- Horn, H.F.; Vousden, K.H. Coping with stress: Multiple ways to activate p53. *Oncogene* **2007**, *26*, 1306–1316. [CrossRef] [PubMed]
- Szybińska, A.; Leśniak, W. P53 Dysfunction in Neurodegenerative Diseases - The Cause or Effect of Pathological Changes? *Aging Dis.* **2017**, *8*, 506–518. [CrossRef]
- Bowen, M.E.; Attardi, L.D. The role of p53 in developmental syndromes. *J. Mol. Cell Biol.* **2019**, *11*, 200–211. [CrossRef] [PubMed]
- Pfister, N.T.; Prives, C. Transcriptional Regulation by Wild-Type and Cancer-Related Mutant Forms of p53. *Cold Spring Harb. Perspect. Med.* **2017**, *7*, a026054. [CrossRef] [PubMed]
- Aubrey, B.J.; Kelly, G.L.; Janic, A.; Herold, M.J.; Strasser, A. How does p53 induce apoptosis and how does this relate to p53-mediated tumour suppression? *Cell Death Differ.* **2018**, *25*, 104–113. [CrossRef] [PubMed]
- Williams, A.B.; Schumacher, B. p53 in the DNA-Damage-Repair Process. *Cold Spring Harb. Perspect. Med.* **2016**, *6*, a026070. [CrossRef] [PubMed]
- Maiuri, M.C.; Galluzzi, L.; Morselli, E.; Kepp, O.; Malik, S.A.; Kroemer, G. Autophagy regulation by p53. *Curr. Opin. Cell Biol.* **2010**, *22*, 181–185. [CrossRef] [PubMed]
- Comel, A.; Sorrentino, G.; Capaci, V.; Del Sal, G. The cytoplasmic side of p53's oncosuppressive activities. *FEBS Lett.* **2014**, *588*, 2600–2609. [CrossRef]
- Brosh, R.; Rotter, V. When mutants gain new powers: News from the mutant p53 field. *Nat. Rev. Cancer* **2009**, *9*, 701–713. [CrossRef] [PubMed]
- Muller, P.A.; Vousden, K.H. Mutant p53 in cancer: New functions and therapeutic opportunities. *Cancer Cell* **2014**, *25*, 304–317. [CrossRef]
- Kruse, J.P.; Gu, W. Modes of p53 regulation. *Cell* **2009**, *137*, 609–622. [CrossRef]
- Lavin, M.F.; Gueven, N. The complexity of p53 stabilization and activation. *Cell Death Differ.* **2006**, *13*, 941–950. [CrossRef]

20. Lucchesi, C.; Zhang, J.; Chen, X. Modulation of the p53 family network by RNA-binding proteins. *Transl. Cancer Res.* **2016**, *5*, 676–684. [[CrossRef](#)]
21. Herrero, A.B.; Rojas, E.A.; Misiewicz-Krzeminska, I.; Krzeminski, P.; Gutiérrez, N.C. Molecular Mechanisms of p53 Deregulation in Cancer: An Overview in Multiple Myeloma. *Int. J. Mol. Sci.* **2016**, *17*, 2003. [[CrossRef](#)]
22. Takagi, M.; Absalon, M.J.; McLure, K.G.; Kastan, M.B. Regulation of p53 translation and induction after DNA damage by ribosomal protein L26 and nucleolin. *Cell* **2005**, *123*, 49–63, correction in **2005**, *123*, 536–537. [[CrossRef](#)]
23. Wedeken, L.; Singh, P.; Klempnauer, K.H. Tumor suppressor protein Pcd4 inhibits translation of p53 mRNA. *J. Biol. Chem.* **2011**, *286*, 42855–42862. [[CrossRef](#)] [[PubMed](#)]
24. Marcel, V.; Dichtel-Danjoy, M.L.; Sagne, C.; Hafsi, H.; Ma, D.; Ortiz-Cuaran, S.; Olivier, M.; Hall, J.; Mollereau, B.; Hainaut, P.; et al. Biological functions of p53 isoforms through evolution: Lessons from animal and cellular models. *Cell Death Differ.* **2011**, *18*, 1815–1824. [[CrossRef](#)]
25. Yin, Y.; Stephen, C.W.; Luciani, M.G.; Fåhræus, R. p53 Stability and activity is regulated by Mdm2-mediated induction of alternative p53 translation products. *Nat. Cell Biol.* **2002**, *4*, 462–467, correction in **2002**, *4*, 912. [[CrossRef](#)] [[PubMed](#)]
26. Vieler, M.; Sanyal, S. p53 Isoforms and Their Implications in Cancer. *Cancers* **2018**, *10*, 288. [[CrossRef](#)]
27. Chen, J.; Ng, S.M.; Chang, C.; Zhang, Z.; Bourdon, J.C.; Lane, D.P.; Peng, J. p53 isoform delta113p53 is a p53 target gene that antagonizes p53 apoptotic activity via BclxL activation in zebrafish. *Genes Dev.* **2009**, *23*, 278–290. [[CrossRef](#)] [[PubMed](#)]
28. Mondal, A.M.; Horikawa, I.; Pine, S.R.; Fujita, K.; Morgan, K.M.; Vera, E.; Mazur, S.J.; Appella, E.; Vojtesek, B.; Blasco, M.A.; et al. p53 isoforms regulate aging- and tumor-associated replicative senescence in T lymphocytes. *J. Clin. Investig.* **2013**, *123*, 5247–5257. [[CrossRef](#)]
29. Turnquist, C.; Horikawa, I.; Foran, E.; Major, E.O.; Vojtesek, B.; Lane, D.P.; Lu, X.; Harris, B.T.; Harris, C.C. p53 isoforms regulate astrocyte-mediated neuroprotection and neurodegeneration. *Cell Death Differ.* **2016**, *23*, 1515–1528. [[CrossRef](#)]
30. Bowen, M.E.; McClendon, J.; Long, H.K.; Sorayya, A.; Van Nostrand, J.L.; Wysocka, J.; Attardi, L.D. The Spatiotemporal Pattern and Intensity of p53 Activation Dictates Phenotypic Diversity in p53-Driven Developmental Syndromes. *Dev. Cell* **2019**, *50*, 212–228. [[CrossRef](#)] [[PubMed](#)]
31. Jones, S.N.; Roe, A.E.; Donehower, L.A.; Bradley, A. Rescue of embryonic lethality in Mdm2-deficient mice by absence of p53. *Nature* **1995**, *378*, 206–208. [[CrossRef](#)] [[PubMed](#)]
32. Mendrysa, S.M.; O’Leary, K.A.; McElwee, M.K.; Michalowski, J.; Eisenman, R.N.; Powell, D.A.; Perry, M.E. Tumor suppression and normal aging in mice with constitutively high p53 activity. *Genes Dev.* **2006**, *20*, 16–21. [[CrossRef](#)] [[PubMed](#)]
33. Wang, Y.V.; Leblanc, M.; Fox, N.; Mao, J.H.; Tinkum, K.L.; Krummel, K.; Engle, D.; Piwnica-Worms, D.; Piwnica-Worms, H.; Balmain, A.; et al. Fine-tuning p53 activity through C-terminal modification significantly contributes to HSC homeostasis and mouse radiosensitivity. *Genes Dev.* **2011**, *25*, 1426–1438. [[CrossRef](#)]
34. Van Nostrand, J.L.; Brady, C.A.; Jung, H.; Fuentes, D.R.; Kozak, M.M.; Johnson, T.M.; Lin, C.Y.; Lin, C.J.; Swiderski, D.L.; Vogel, H.; et al. Inappropriate p53 activation during development induces features of CHARGE syndrome. *Nature* **2014**, *514*, 228–232. [[CrossRef](#)] [[PubMed](#)]
35. Positional cloning of a gene involved in the pathogenesis of Treacher Collins syndrome. The Treacher Collins Syndrome Collaborative Group. *Nat Genet.* **1996**, *12*, 130–136. [[CrossRef](#)] [[PubMed](#)]
36. Dixon, J.; Jones, N.C.; Sandell, L.L.; Jaysinghe, S.M.; Crane, J.; Rey, J.P.; Dixon, M.J.; Trainor, P.A. Tcof1/Treacle is required for neural crest cell formation and proliferation deficiencies that cause craniofacial abnormalities. *Proc. Natl. Acad. Sci. USA* **2006**, *103*, 13403–13408. [[CrossRef](#)] [[PubMed](#)]
37. Rubbi, C.P.; Milner, J. Disruption of the nucleolus mediates stabilization of p53 in response to DNA damage and other stresses. *EMBO J.* **2003**, *22*, 6068–6077. [[CrossRef](#)] [[PubMed](#)]
38. Jones, N.C.; Lynn, M.L.; Gaudenz, K.; Sakai, D.; Aoto, K.; Rey, J.P.; Glynn, E.F.; Ellington, L.; Du, C.; Dixon, J.; et al. Prevention of the neurocristopathy Treacher Collins syndrome through inhibition of p53 function. *Nat. Med.* **2008**, *14*, 125–133. [[CrossRef](#)] [[PubMed](#)]
39. Narla, A.; Ebert, B.L. Ribosomopathies: Human disorders of ribosome dysfunction. *Blood* **2010**, *115*, 3196–3205. [[CrossRef](#)] [[PubMed](#)]
40. Deisenroth, C.; Franklin, D.A.; Zhang, Y. The Evolution of the Ribosomal Protein-MDM2-p53 Pathway. *Cold Spring Harb. Perspect. Med.* **2016**, *6*, a026138. [[CrossRef](#)]
41. Holohan, B.; Wright, W.E.; Shay, J.W. Cell biology of disease: Telomeropathies: An emerging spectrum disorder. *J. Cell Biol.* **2014**, *205*, 289–299. [[CrossRef](#)]
42. Lee, Y.; Choi, I.; Kim, J.; Kim, K. DNA damage to human genetic disorders with neurodevelopmental defects. *J. Genet. Med.* **2016**, *13*, 1–13. [[CrossRef](#)]
43. O’Neill, R.S.; Schoborg, T.A.; Rusan, N.M. Same but different: Pleiotropy in centrosome-related microcephaly. *Mol. Biol. Cell* **2018**, *29*, 241–246. [[CrossRef](#)]
44. Van Nostrand, J.L.; Attardi, L.D. Guilty as CHARGED: p53’s expanding role in disease. *Cell Cycle* **2014**, *13*, 3798–3807. [[CrossRef](#)]
45. Hart, J.; Miriyala, K. Neural tube defects in Waardenburg syndrome: A case report and review of the literature. *Am. J. Med. Genet. A* **2017**, *173*, 2472–2477. [[CrossRef](#)]
46. Du, Q.; de la Morena, M.T.; van Oers, N.S.C. The Genetics and Epigenetics of 22q11.2 Deletion Syndrome. *Front. Genet.* **2020**, *10*, 1365. [[CrossRef](#)] [[PubMed](#)]

47. Halperin, D.S.; Freedman, M.H. Diamond-blackfan anemia: Etiology, pathophysiology, and treatment. *Am. J. Pediatr. Hematol. Oncol.* **1989**, *11*, 380–394.
48. Jaako, P.; Flygare, J.; Olsson, K.; Quere, R.; Ehinger, M.; Henson, A.; Ellis, S.; Schambach, A.; Baum, C.; Richter, J.; et al. Mice with ribosomal protein S19 deficiency develop bone marrow failure and symptoms like patients with Diamond-Blackfan anemia. *Blood* **2011**, *118*, 6087–6096. [[CrossRef](#)] [[PubMed](#)]
49. Barlow, J.L.; Drynan, L.F.; Hewett, D.R.; Holmes, L.R.; Lorenzo-Abalde, S.; Lane, A.L.; Jolin, H.E.; Pannell, R.; Middleton, A.J.; Wong, S.H.; et al. A p53-dependent mechanism underlies macrocytic anemia in a mouse model of human 5q- syndrome. *Nat. Med.* **2010**, *16*, 59–66. [[CrossRef](#)] [[PubMed](#)]
50. Liu, Y.; Deisenroth, C.; Zhang, Y. RP-MDM2-p53 Pathway: Linking Ribosomal Biogenesis and Tumor Surveillance. *Trends Cancer* **2016**, *2*, 191–204. [[CrossRef](#)]
51. Farley-Barnes, K.I.; Ogawa, L.M.; Baserga, S.J. Ribosomopathies: Old Concepts, New Controversies. *Trends Genet.* **2019**, *35*, 754–767. [[CrossRef](#)]
52. Kampen, K.R.; Sulima, S.O.; Vereecke, S.; De Keersmaecker, K. Hallmarks of ribosomopathies. *Nucleic Acids Res.* **2020**, *48*, 1013–1028. [[CrossRef](#)] [[PubMed](#)]
53. Dai, M.S.; Arnold, H.; Sun, X.X.; Sears, R.; Lu, H. Inhibition of c-Myc activity by ribosomal protein L11. *EMBO J.* **2007**, *26*, 3332–3345, correction in **2009**, *28*, 993. [[CrossRef](#)] [[PubMed](#)]
54. Liao, J.M.; Zhou, X.; Gatignol, A.; Lu, H. Ribosomal proteins L5 and L11 co-operatively inactivate c-Myc via RNA-induced silencing complex. *Oncogene* **2014**, *33*, 4916–4923. [[CrossRef](#)] [[PubMed](#)]
55. Morgado-Palacin, L.; Varetto, G.; Llanos, S.; Gómez-López, G.; Martinez, D.; Serrano, M. Partial Loss of Rpl11 in Adult Mice Recapitulates Diamond-Blackfan Anemia and Promotes Lymphomagenesis. *Cell Rep.* **2015**, *13*, 712–722. [[CrossRef](#)]
56. Ludwig, L.S.; Gazda, H.T.; Eng, J.C.; Eichhorn, S.W.; Thiru, P.; Ghazvinian, R.; George, T.I.; Gotlib, J.R.; Beggs, A.H.; Sieff, C.A.; et al. Altered translation of GATA1 in Diamond-Blackfan anemia. *Nat. Med.* **2014**, *20*, 748–753. [[CrossRef](#)] [[PubMed](#)]
57. Khajuria, R.K.; Munschauer, M.; Ulirsch, J.C.; Fiorini, C.; Ludwig, L.S.; McFarland, S.K.; Abdulhay, N.J.; Specht, H.; Keshishian, H.; Mani, D.R.; et al. Ribosome Levels Selectively Regulate Translation and Lineage Commitment in Human Hematopoiesis. *Cell* **2018**, *173*, 90–103. [[CrossRef](#)]
58. Li, D.; Wang, J. Ribosome heterogeneity in stem cells and development. *J. Cell Biol.* **2020**, *219*, e202001108. [[CrossRef](#)] [[PubMed](#)]
59. Norris, K.; Hopes, T.; Aspden, J.L. Ribosome heterogeneity and specialization in development. *Wiley Interdiscip. Rev. RNA* **2021**, *12*, e1644. [[CrossRef](#)]
60. Favaro, F.P.; Alvizi, L.; Zechi-Ceide, R.M.; Bertola, D.; Felix, T.M.; de Souza, J.; Raskin, S.; Twigg, S.R.; Weiner, A.M.; Armas, P.; et al. A noncoding expansion in EIF4A3 causes Richieri-Costa-Pereira syndrome, a craniofacial disorder associated with limb defects. *Am. J. Hum. Genet.* **2014**, *94*, 120–128. [[CrossRef](#)]
61. Albers, C.A.; Paul, D.S.; Schulze, H.; Freson, K.; Stephens, J.C.; Smethurst, P.A.; Jolley, J.D.; Cvejic, A.; Kostadima, M.; Bertone, P.; et al. Compound inheritance of a low-frequency regulatory SNP and a rare null mutation in exon-junction complex subunit RBM8A causes TAR syndrome. *Nat. Genet.* **2012**, *44*, 435–439. [[CrossRef](#)]
62. Rosenfeld, J.A.; Traylor, R.N.; Schaefer, G.B.; McPherson, E.W.; Ballif, B.C.; Klopocki, E.; Mundlos, S.; Shaffer, L.G.; Aylsworth, A.S.; 1q21.1 Study Group. Proximal microdeletions and microduplications of 1q21.1 contribute to variable abnormal phenotypes. *Eur. J. Hum. Genet.* **2012**, *20*, 754–761. [[CrossRef](#)]
63. Mao, H.; Pilaz, L.J.; McMahon, J.J.; Golzio, C.; Wu, D.; Shi, L.; Katsanis, N.; Silver, D.L. Rbm8a haploinsufficiency disrupts embryonic cortical development resulting in microcephaly. *J. Neurosci.* **2015**, *35*, 7003–7018. [[CrossRef](#)]
64. Mao, H.; McMahon, J.J.; Tsai, Y.H.; Wang, Z.; Silver, D.L. Haploinsufficiency for Core Exon Junction Complex Components Disrupts Embryonic Neurogenesis and Causes p53-Mediated Microcephaly. *PLoS Genet.* **2016**, *12*, e1006282. [[CrossRef](#)]
65. Su, C.H.; Liao, W.J.; Ke, W.C.; Yang, R.B.; Tarn, W.Y. The Y14-p53 regulatory circuit in megakaryocyte differentiation and thrombocytopenia. *bioRxiv* **2020**. [[CrossRef](#)]
66. Silver, D.L.; Watkins-Chow, D.E.; Schreck, K.C.; Pierfelice, T.J.; Larson, D.M.; Burnetti, A.J.; Liaw, H.J.; Myung, K.; Walsh, C.A.; Gaiano, N.; et al. The exon junction complex component Magoh controls brain size by regulating neural stem cell division. *Nat. Neurosci.* **2010**, *13*, 551–558. [[CrossRef](#)]
67. Chuang, T.W.; Lu, C.C.; Su, C.H.; Wu, P.Y.; Easwaran, S.; Lee, C.C.; Kuo, H.C.; Hung, K.Y.; Lee, K.M.; Tsai, C.Y.; et al. The RNA Processing Factor Y14 Participates in DNA Damage Response and Repair. *iScience* **2019**, *13*, 402–415. [[CrossRef](#)] [[PubMed](#)]
68. Kwon, O.S.; Mishra, R.; Safieddine, A.; Coleno, E.; Alasseur, Q.; Faucourt, M.; Barbosa, I.; Bertrand, E.; Spassky, N.; Le Hir, H. Exon junction complex dependent mRNA localization is linked to centrosome organization during ciliogenesis. *Nat. Commun.* **2021**, *12*, 1351. [[CrossRef](#)]
69. Lu, C.C.; Lee, C.C.; Tseng, C.T.; Tarn, W.Y. Y14 governs p53 expression and modulates DNA damage sensitivity. *Sci. Rep.* **2017**, *7*, 45558.
70. Taylor, A.M.R.; Rothblum-Oviatt, C.; Ellis, N.A.; Hickson, I.D.; Meyer, S.; Crawford, T.O.; Smogorzewska, A.; Pietrucha, B.; Weemaes, C.; Stewart, G.S. Chromosome instability syndromes. *Nat. Rev. Dis. Primers* **2019**, *5*, 64. [[CrossRef](#)] [[PubMed](#)]
71. Szczepanski, J.T.; Jacobs, A.C.; Van Houten, B.; Greenberg, M.M. Double-strand break formation during nucleotide excision repair of a DNA interstrand cross-link. *Biochemistry* **2009**, *48*, 7565–7567. [[CrossRef](#)]
72. Ceccaldi, R.; Sarangi, P.; D’Andrea, A.D. The Fanconi anaemia pathway: New players and new functions. *Nat. Rev. Mol. Cell Biol.* **2016**, *17*, 337–349. [[CrossRef](#)]

73. Rodríguez, A.; D'Andrea, A. Fanconi anemia pathway. *Curr Biol.* **2017**, *27*, R986–R988. [[CrossRef](#)]
74. García-Muse, T.; Aguilera, A. Transcription-replication conflicts: How they occur and how they are resolved. *Nat. Rev. Mol. Cell Biol.* **2016**, *17*, 553–563. [[CrossRef](#)] [[PubMed](#)]
75. Bianchi, F.T.; Berto, G.E.; Di Cunto, F. Impact of DNA repair and stability defects on cortical development. *Cell Mol. Life Sci.* **2018**, *75*, 3963–3976. [[CrossRef](#)] [[PubMed](#)]
76. Niraj, J.; Färkkilä, A.; D'Andrea, A.D. The Fanconi Anemia Pathway in Cancer. *Annu. Rev. Cancer Biol.* **2019**, *3*, 457–478. [[CrossRef](#)] [[PubMed](#)]
77. Ceccaldi, R.; Parmar, K.; Mouly, E.; Delord, M.; Kim, J.M.; Regairaz, M.; Pla, M.; Vasquez, N.; Zhang, Q.S.; Pondarre, C.; et al. Bone marrow failure in Fanconi anemia is triggered by an exacerbated p53/p21 DNA damage response that impairs hematopoietic stem and progenitor cells. *Cell Stem Cell.* **2012**, *11*, 36–49. [[CrossRef](#)] [[PubMed](#)]
78. Sii-Felice, K.; Etienne, O.; Hoffschir, F.; Mathieu, C.; Riou, L.; Barroca, V.; Haton, C.; Arwert, F.; Fouchet, P.; Boussin, F.D.; et al. Fanconi DNA repair pathway is required for survival and long-term maintenance of neural progenitors. *EMBO J.* **2008**, *27*, 770–781. [[CrossRef](#)]
79. Brugarolas, J.; Jacks, T. Double indemnity: p53, BRCA and cancer. p53 mutation partially rescues developmental arrest in Brca1 and Brca2 null mice, suggesting a role for familial breast cancer genes in DNA damage repair. *Nat. Med.* **1997**, *3*, 721–722. [[CrossRef](#)]
80. Adam, J.; Deans, B.; Thacker, J. A role for Xrcc2 in the early stages of mouse development. *DNA Repair* **2007**, *6*, 224–234. [[CrossRef](#)] [[PubMed](#)]
81. Lim, D.S.; Hasty, P. A mutation in mouse rad51 results in an early embryonic lethal that is suppressed by a mutation in p53. *Mol. Cell. Biol.* **1996**, *16*, 7133–7143. [[CrossRef](#)]
82. Woodbine, L.; Gennery, A.R.; Jeggo, P.A. The clinical impact of deficiency in DNA non-homologous end-joining. *DNA Repair* **2014**, *16*, 84–96. [[CrossRef](#)] [[PubMed](#)]
83. Frank, K.M.; Sharpless, N.E.; Gao, Y.; Sekiguchi, J.M.; Ferguson, D.O.; Zhu, C.; Manis, J.P.; Horner, J.; DePinho, R.A.; Alt, F.W. DNA ligase IV deficiency in mice leads to defective neurogenesis and embryonic lethality via the p53 pathway. *Mol. Cell.* **2000**, *5*, 993–1002. [[CrossRef](#)]
84. Gao, Y.; Ferguson, D.O.; Xie, W.; Manis, J.P.; Sekiguchi, J.; Frank, K.M.; Chaudhuri, J.; Horner, J.; DePinho, R.A.; Alt, F.W. Interplay of p53 and DNA-repair protein XRCC4 in tumorigenesis, genomic stability and development. *Nature* **2000**, *404*, 897–900.
85. Jiang, W.; Crowe, J.L.; Liu, X.; Nakajima, S.; Wang, Y.; Li, C.; Lee, B.J.; Dubois, R.L.; Liu, C.; Yu, X.; et al. Differential phosphorylation of DNA-PKcs regulates the interplay between end-processing and end-ligation during nonhomologous end-joining. *Mol. Cell* **2015**, *58*, 172–185. [[CrossRef](#)]
86. Lamarche, B.J.; Orazio, N.I.; Weitzman, M.D. The MRN complex in double-strand break repair and telomere maintenance. *FEBS Lett.* **2010**, *584*, 3682–3695. [[CrossRef](#)]
87. Chrzanowska, K.H.; Gregorek, H.; Dembowska-Bagińska, B.; Kalina, M.A.; Digweed, M. Nijmegen breakage syndrome (NBS). *Orphanet J. Rare Dis.* **2012**, *7*, 13. [[CrossRef](#)]
88. Frappart, P.O.; Tong, W.M.; Demuth, I.; Radovanovic, I.; Herceg, Z.; Aguzzi, A.; Digweed, M.; Wang, Z.Q. An essential function for NBS1 in the prevention of ataxia and cerebellar defects. *Nat. Med.* **2005**, *11*, 538–544. [[CrossRef](#)]
89. Jaber, S.; Toufektchan, E.; Lejour, V.; Bardot, B.; Toledo, F. p53 downregulates the Fanconi anaemia DNA repair pathway. *Nat. Commun.* **2016**, *7*, 11091. [[CrossRef](#)]
90. Pfeiffer, V.; Lingner, J. Replication of telomeres and the regulation of telomerase. *Cold Spring Harb. Perspect. Biol.* **2013**, *5*, a010405. [[CrossRef](#)]
91. Maciejowski, J.; de Lange, T. Telomeres in cancer: Tumour suppression and genome instability. *Nat. Rev. Mol. Cell Biol.* **2017**, *18*, 175–186, correction in **2019**, *20*, 259. [[CrossRef](#)] [[PubMed](#)]
92. Mochizuki, Y.; He, J.; Kulkarni, S.; Bessler, M.; Mason, P.J. Mouse dyskerin mutations affect accumulation of telomerase RNA and small nucleolar RNA, telomerase activity, and ribosomal RNA processing. *Proc. Natl. Acad. Sci. USA* **2004**, *101*, 10756–10761. [[CrossRef](#)] [[PubMed](#)]
93. Ge, J.; Rudnick, D.A.; He, J.; Crimmins, D.L.; Ladenson, J.H.; Bessler, M.; Mason, P.J. Dyskerin ablation in mouse liver inhibits rRNA processing and cell division. *Mol. Cell Biol.* **2010**, *30*, 413–422. [[CrossRef](#)] [[PubMed](#)]
94. Pereboeva, L.; Hubbard, M.; Goldman, F.D.; Westin, E.R. Robust DNA Damage Response and Elevated Reactive Oxygen Species in TINF2-Mutated Dyskeratosis Congenita Cells. *PLoS ONE* **2016**, *11*, e0148793. [[CrossRef](#)]
95. Ferrón, S.R.; Marqués-Torrejón, M.A.; Mira, H.; Flores, I.; Taylor, K.; Blasco, M.A.; Fariñas, I. Telomere shortening in neural stem cells disrupts neuronal differentiation and neurogenesis. *J. Neurosci.* **2009**, *29*, 14394–14407. [[CrossRef](#)] [[PubMed](#)]
96. Tejera, A.M.; Stagno d'Alcontres, M.; Thanasoula, M.; Marion, R.M.; Martinez, P.; Liao, C.; Flores, J.M.; Tarsounas, M.; Blasco, M.A. TPP1 is required for TERT recruitment, telomere elongation during nuclear reprogramming, and normal skin development in mice. *Dev. Cell* **2010**, *18*, 775–789. [[CrossRef](#)] [[PubMed](#)]
97. Benyelles, M.; Episkopou, H.; O'Donohue, M.F.; Kermasson, L.; Frange, P.; Poulain, F.; Burcu Belen, F.; Polat, M.; Bole-Feysot, C.; Langa-Vives, F.; et al. Impaired telomere integrity and rRNA biogenesis in PARN-deficient patients and knock-out models. *EMBO Mol. Med.* **2019**, *11*, e10201. [[CrossRef](#)] [[PubMed](#)]

98. Toufektchan, E.; Lejour, V.; Durand, R.; Giri, N.; Draskovic, I.; Bardot, B.; Laplante, P.; Jaber, S.; Alter, B.P.; Londono-Vallejo, J.A.; et al. Germline mutation of *MDM4*, a major p53 regulator, in a familial syndrome of defective telomere maintenance. *Sci. Adv.* **2020**, *6*, eaay3511. [[CrossRef](#)] [[PubMed](#)]
99. Simeonova, I.; Jaber, S.; Draskovic, I.; Bardot, B.; Fang, M.; Bouarich-Bourimi, R.; Lejour, V.; Charbonnier, L.; Soudais, C.; Bourdon, J.C.; et al. Mutant mice lacking the p53 C-terminal domain model telomere syndromes. *Cell Rep.* **2013**, *3*, 2046–2058. [[CrossRef](#)]
100. Tummala, H.; Walne, A.; Collopy, L.; Cardoso, S.; de la Fuente, J.; Lawson, S.; Powell, J.; Cooper, N.; Foster, A.; Mohammed, S.; et al. Poly(A)-specific ribonuclease deficiency impacts telomere biology and causes dyskeratosis congenita. *J. Clin. Investig.* **2015**, *125*, 2151–2160. [[CrossRef](#)]
101. Gönczy, P. Towards a molecular architecture of centriole assembly. *Nat. Rev. Mol. Cell Biol.* **2012**, *13*, 425–435. [[CrossRef](#)] [[PubMed](#)]
102. Cosenza, M.R.; Krämer, A. Centrosome amplification, chromosomal instability and cancer: Mechanistic, clinical and therapeutic issues. *Chromosome Res.* **2016**, *24*, 105–126. [[CrossRef](#)]
103. Wu, Q.; Li, B.; Liu, L.; Sun, S.; Sun, S. Centrosome dysfunction: A link between senescence and tumor immunity. *Signal Transduct. Target. Ther.* **2020**, *5*, 107. [[CrossRef](#)] [[PubMed](#)]
104. LoMastro, G.M.; Holland, A.J. The Emerging Link between Centrosome Aberrations and Metastasis. *Dev. Cell* **2019**, *49*, 325–331. [[CrossRef](#)]
105. Haren, L.; Remy, M.H.; Bazin, I.; Callebaut, I.; Wright, M.; Merdes, A. NEDD1-dependent recruitment of the gamma-tubulin ring complex to the centrosome is necessary for centriole duplication and spindle assembly. *J. Cell Biol.* **2006**, *172*, 505–515. [[CrossRef](#)]
106. Goundiam, O.; Basto, R. Centrosomes in disease: How the same music can sound so different? *Curr. Opin. Struct. Biol.* **2021**, *66*, 74–82. [[CrossRef](#)]
107. Siskos, N.; Stylianopoulou, E.; Skavdis, G.; Grigoriou, M.E. Molecular Genetics of Microcephaly Primary Hereditary: An Overview. *Brain Sci.* **2021**, *11*, 581. [[CrossRef](#)] [[PubMed](#)]
108. Fish, J.L.; Kosodo, Y.; Enard, W.; Pääbo, S.; Huttner, W.B. Aspm specifically maintains symmetric proliferative divisions of neuroepithelial cells. *Proc. Natl. Acad. Sci. USA* **2006**, *103*, 10438–10443. [[CrossRef](#)]
109. Williams, S.E.; Garcia, I.; Crowther, A.J.; Li, S.; Stewart, A.; Liu, H.; Lough, K.J.; O’Neill, S.; Veleta, K.; Oyarzabal, E.A.; et al. Aspm sustains postnatal cerebellar neurogenesis and medulloblastoma growth in mice. *Development* **2015**, *142*, 3921–3932. [[CrossRef](#)]
110. Gai, M.; Bianchi, F.T.; Vagnoni, C.; Verni, F.; Bonaccorsi, S.; Pasquero, S.; Berto, G.E.; Sgrò, F.; Chiotto, A.M.; Annaratone, L.; et al. ASPM and CITK regulate spindle orientation by affecting the dynamics of astral microtubules. *EMBO Rep.* **2016**, *17*, 1396–1409. [[CrossRef](#)]
111. Bianchi, F.T.; Tocco, C.; Pallavicini, G.; Liu, Y.; Verni, F.; Merigliano, C.; Bonaccorsi, S.; El-Assawy, N.; Priano, L.; Gai, M.; et al. Citron Kinase Deficiency Leads to Chromosomal Instability and TP53-Sensitive Microcephaly. *Cell Rep.* **2017**, *18*, 1674–1686. [[CrossRef](#)]
112. Klingseisen, A.; Jackson, A.P. Mechanisms and pathways of growth failure in primordial dwarfism. *Genes Dev.* **2011**, *25*, 2011–2024. [[CrossRef](#)] [[PubMed](#)]
113. Brown, N.J.; Marjanović, M.; Lüders, J.; Stracker, T.H.; Costanzo, V. Cep63 and cep152 cooperate to ensure centriole duplication. *PLoS ONE* **2013**, *8*, e69986. [[CrossRef](#)] [[PubMed](#)]
114. Marjanović, M.; Sánchez-Huertas, C.; Terré, B.; Gómez, R.; Scheel, J.F.; Pacheco, S.; Knobel, P.A.; Martínez-Marchal, A.; Aivio, S.; Palenzuela, L.; et al. CEP63 deficiency promotes p53-dependent microcephaly and reveals a role for the centrosome in meiotic recombination. *Nat. Commun.* **2015**, *6*, 7676. [[CrossRef](#)] [[PubMed](#)]
115. Monda, J.K.; Cheeseman, I.M. Nde1 promotes diverse dynein functions through differential interactions and exhibits an isoform-specific proteasome association. *Mol. Biol. Cell* **2018**, *29*, 2336–2345. [[CrossRef](#)] [[PubMed](#)]
116. Phan, T.P.; Maryniak, A.L.; Boatwright, C.A.; Lee, J.; Atkins, A.; Tijhuis, A.; Spierings, D.C.; Bazzi, H.; Foijer, F.; Jordan, P.W.; et al. Centrosome defects cause microcephaly by activating the 53BP1-USP28-TP53 mitotic surveillance pathway. *EMBO J.* **2021**, *40*, e106118. [[CrossRef](#)]
117. Ruggero, D.; Grisendi, S.; Piazza, F.; Rego, E.; Mari, F.; Rao, P.H.; Cordon-Cardo, C.; Pandolfi, P.P. Dyskeratosis congenita and cancer in mice deficient in ribosomal RNA modification. *Science* **2003**, *299*, 259–262. [[CrossRef](#)]
118. Yoon, A.; Peng, G.; Brandenburger, Y.; Zollo, O.; Xu, W.; Rego, E.; Ruggero, D. Impaired control of IRES-mediated translation in X-linked dyskeratosis congenita. *Science* **2006**, *312*, 902–906. [[CrossRef](#)] [[PubMed](#)]
119. Penzo, M.; Montanaro, L. Turning Uridines around: Role of rRNA Pseudouridylation in Ribosome Biogenesis and Ribosomal Function. *Biomolecules* **2018**, *8*, 38. [[CrossRef](#)] [[PubMed](#)]
120. Farooq, M.; Lindbæk, L.; Krogh, N.; Doganli, C.; Keller, C.; Mönnich, M.; Gonçalves, A.B.; Sakthivel, S.; Mang, Y.; Fatima, A.; et al. RRP7A links primary microcephaly to dysfunction of ribosome biogenesis, resorption of primary cilia, and neurogenesis. *Nat. Commun.* **2020**, *11*, 5816. [[CrossRef](#)]
121. Smith, E.; Dejsuphong, D.; Balestrini, A.; Hampel, M.; Lenz, C.; Takeda, S.; Vindigni, A.; Costanzo, V. An ATM- and ATR-dependent checkpoint inactivates spindle assembly by targeting CEP63. *Nat. Cell Biol.* **2009**, *11*, 278–285. [[CrossRef](#)]
122. Nalepa, G.; Enzor, R.; Sun, Z.; Marchal, C.; Park, S.J.; Yang, Y.; Tedeschi, L.; Kelich, S.; Hanenberg, H.; Clapp, D.W. Fanconi anemia signaling network regulates the spindle assembly checkpoint. *J. Clin. Investig.* **2013**, *123*, 3839–3847. [[CrossRef](#)]
123. Gueiderikh, A.; Maczkowiak-Chartois, F.; Rouvet, G.; Souquère-Besse, S.; Apcher, S.; Diaz, J.J.; Rosselli, F. Fanconi anemia A protein participates in nucleolar homeostasis maintenance and ribosome biogenesis. *Sci. Adv.* **2021**, *7*, eabb5414. [[CrossRef](#)]

124. Sohn, D.; Graupner, V.; Neise, D.; Essmann, F.; Schulze-Osthoff, K.; Jänicke, R.U. Pifithrin-alpha protects against DNA damage-induced apoptosis downstream of mitochondria independent of p53. *Cell Death Differ.* **2009**, *16*, 869–878. [[CrossRef](#)]
125. Dutt, S.; Narla, A.; Lin, K.; Mullally, A.; Abayasekara, N.; Megerdichian, C.; Wilson, F.H.; Currie, T.; Khanna-Gupta, A.; Berliner, N.; et al. Haploinsufficiency for ribosomal protein genes causes selective activation of p53 in human erythroid progenitor cells. *Blood* **2011**, *117*, 2567–2576. [[CrossRef](#)]
126. Taylor, A.M.; Macari, E.R.; Chan, I.T.; Blair, M.C.; Doulatov, S.; Vo, L.T.; Raiser, D.M.; Siva, K.; Basak, A.; Pirouz, M.; et al. Calmodulin inhibitors improve erythropoiesis in Diamond-Blackfan anemia. *Sci. Transl. Med.* **2020**, *12*, eabb5831. [[CrossRef](#)] [[PubMed](#)]
127. Ubby, I.; Krueger, C.; Rosato, R.; Qian, W.; Chang, J.; Sabapathy, K. Cancer therapeutic targeting using mutant-p53-specific siRNAs. *Oncogene* **2019**, *38*, 3415–3427. [[CrossRef](#)]
128. Jaako, P.; Debnath, S.; Olsson, K.; Bryder, D.; Flygare, J.; Karlsson, S. Dietary L-leucine improves the anemia in a mouse model for Diamond-Blackfan anemia. *Blood* **2012**, *120*, 2225–2228. [[CrossRef](#)] [[PubMed](#)]
129. Payne, E.M.; Virgilio, M.; Narla, A.; Sun, H.; Levine, M.; Paw, B.H.; Berliner, N.; Look, A.T.; Ebert, B.L.; Khanna-Gupta, A. L-Leucine improves the anemia and developmental defects associated with Diamond-Blackfan anemia and del(5q) MDS by activating the mTOR pathway. *Blood* **2012**, *120*, 2214–2224. [[CrossRef](#)] [[PubMed](#)]
130. Sakai, D.; Dixon, J.; Achilleos, A.; Dixon, M.; Trainor, P.A. Prevention of Treacher Collins syndrome craniofacial anomalies in mouse models via maternal antioxidant supplementation. *Nat. Commun.* **2016**, *7*, 10328. [[CrossRef](#)]
131. de Peralta, M.S.; Mouguelar, V.S.; Sdrigotti, M.A.; Ishiy, F.A.; Fanganiello, R.D.; Passos-Bueno, M.R.; Coux, G.; Calcaterra, N.B. Cnbp ameliorates Treacher Collins Syndrome craniofacial anomalies through a pathway that involves redox-responsive genes. *Cell Death Dis.* **2016**, *7*, e2397. [[CrossRef](#)]
132. Rosas, M.G.; Lorenzatti, A.; Porcel de Peralta, M.S.; Calcaterra, N.B.; Coux, G. Proteasomal inhibition attenuates craniofacial malformations in a zebrafish model of Treacher Collins Syndrome. *Biochem. Pharmacol.* **2019**, *163*, 362–370. [[CrossRef](#)] [[PubMed](#)]
133. Grossmann, M. Danazol Treatment for Telomere Diseases. *N. Engl. J. Med.* **2016**, *375*, 1095. [[PubMed](#)]
134. Zhou, L.; McMahon, C.; Bhagat, T.; Alencar, C.; Yu, Y.; Fazzari, M.; Sohal, D.; Heuck, C.; Gundabolu, K.; Ng, C.; et al. Reduced SMAD7 leads to overactivation of TGF-beta signaling in MDS that can be reversed by a specific inhibitor of TGF-beta receptor I kinase. *Cancer Res.* **2011**, *71*, 955–963. [[CrossRef](#)]
135. Zhang, H.; Kozono, D.E.; O'Connor, K.W.; Vidal-Cardenas, S.; Rousseau, A.; Hamilton, A.; Moreau, L.; Gaudio, E.F.; Greenberger, J.; Bagby, G.; et al. TGF- β Inhibition Rescues Hematopoietic Stem Cell Defects and Bone Marrow Failure in Fanconi Anemia. *Cell Stem Cell* **2016**, *18*, 668–681. [[CrossRef](#)] [[PubMed](#)]
136. Río, P.; Navarro, S.; Bueren, J.A. Advances in Gene Therapy for Fanconi Anemia. *Hum. Gene Ther.* **2018**, *29*, 1114–1123. [[CrossRef](#)] [[PubMed](#)]
137. Sanz, E.; Bean, J.C.; Carey, D.P.; Quintana, A.; McKnight, G.S. RiboTag: Ribosomal Tagging Strategy to Analyze Cell-Type-Specific mRNA Expression In Vivo. *Curr. Protoc. Neurosci.* **2019**, *88*, e77. [[CrossRef](#)]
138. Ribezzo, F.; Snoeren, I.A.M.; Ziegler, S.; Stoelben, J.; Olofsen, P.A.; Henic, A.; Ferreira, M.V.; Chen, S.; Stalman, U.S.A.; Buesche, G.; et al. Rps14, Csnk1a1 and miRNA145/miRNA146a deficiency cooperate in the clinical phenotype and activation of the innate immune system in the 5q- syndrome. *Leukemia* **2019**, *33*, 1759–1772. [[CrossRef](#)]